Answers are grounded in this paper and cite their sources.
Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.
No takes yet. Share an insight, caveat, or question.
Sobh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: